Kevin is a health care and FDA regulatory attorney and member of the Life Sciences Health Industry Group. He advises clients across the life sciences and health care spectrum about health care and FDA regulatory issues related to the manufacturing, distribution, and sale of drugs (Rx, OTC, homeopathic), biologics, devices (Rx and OTC), and dietary supplements. His clients include suppliers, manufacturers; repackagers; wholesale and private label distributors; pharmacies (503A, 503B, nuclear); and health care providers.
Kevin specializes in providing legal and strategic advice regarding advertising and promotion, FDA enforcement, and supply chain security (e.g., global product sourcing and distribution, manufacturing and inspections, compounding, recalls, and import/export issues). He is a sought-after counselor for clients looking for long-term, multi-year support for their legal departments. Kevin also regularly advises strategic owners, private equity funds, underwriters and other public and privately-held businesses seeking specialized support in connection with health care financing and securities transactions, and domestic and international mergers and acquisitions. Clients greatly appreciate his added value to transactions from both a legal and business perspective.
Kevin is currently serving a three year term on the Food and Drug Law Institute’s (FDLI’s) Medical Device Committee. He has served on planning committees for FDLI conferences and is a founding member of the Young Lawyers Committee for the Lawyer’s Committee on Civil Rights. A member of the firmwide Pro Bono Committee, Kevin is also the Pro Bono Committee Chair of Reed Smith's Washington, D.C. office.